AMRI signs two-year discovery services agreement with Knopp Biosciences
Includes medicinal chemistry, DMPK and CADD
AMRI, a US provider of contract services to pharma and biotech services, has entered into a new strategic agreement with Knopp Biosciences.
Knopp, based in Pittsburgh, PA, is a drug discovery and development company focused on breakthrough treatments for unmet needs in neurological disorders.
Under the two-year agreement, Albany, NY-based AMRI will provide various discovery-related services that include medicinal chemistry, DMPK and computer-aided drug discovery (CADD).
AMRI scientists will collaborate with Knopp scientists and project leaders on selected novel drug discovery programmes. The collaboration could be extended by mutual agreement.
AMRI’s chairman, president and ceo, Thomas D'Ambra, said: ‘This agreement will combine AMRI’s broad range of drug discovery capabilities, with more than 20 years of CNS experience, to assist Knopp in its goal of delivering safe and effective treatments for unmet medical need.’
This agreement builds on the strategic business relationship that already exists between Knopp Biosciences and AMRI. Since 2006, AMRI has worked with Knopp to provide early process development work, route development, and small-scale and large-scale cGMP manufacturing, as well as analytical method development and validation support.
